XynaRx Pharmaceuticals Corp.
ENHANCING EXISTING PHARMACEUTICAL PRODUCTS WITH PLANT DERIVED CANNABINOIDS THROUGH RESEARCH AND DEVELOPMENT
XynaRx Pharmaceuticals Corp.
XynaRx has established a position in the enhancement of existing pharmaceutical products with plant-derived cannabinoids through research and development processes, formulation expertise and manufacturing know-how. Research and development will be conducted in-house for incorporating Cannabinoids into number of Products. The company has focused on the following 5 major categories:
BUILDING A STATE-OF-THE-ART PRODUCTION FACILITY
WELL SEASONED PHARMACEUTICAL PROFESSIONALS
TARGETING A $300+B AND GROWING MARKET
APPLYING FOR APPROVAL FOR NPN
(NATURAL PRODUCT NUMBER)
AND DIN (DRUG IDENTIFICATION NUMBER)
Formulations
LIST OF SOME OF THE PHARMACEUTICAL FORMULATIONS IN OUR DATABASE
ACETAMINOPHEN 100 ORAL DROP
ACETAMINOPHEN 325 SCORED TABLETS
ACETAMINOPHEN 500 TABLET
IBUPROFEN 400 MG F.C TABLET
IBUPROFEN 200 MG F.C TABLET
PANTOPRAZOLE 40 MG TABLET
CALCIUM D3 250 MG/ 300 IU TABLETS
MELATONIN 3 MG SCORED TABLET
VITAMIN D3/1000 SOFT GEL CAPSULE
VITAMIN D3/1000 IU F.C (FILM-COATED) TABLETS
CALCIUM PLUS TABLET
VITAMIN A+ D3+ ZN+ FE ORAL DROP
VITAMIN E 400 SOFT GEL CAPSULE
MULTIVITAMIN PLUS MINERAL CAPSULES
FERROUS SULPHATE SRI/ FOLIC ACID/ ZINC SULPHATE 150/0.5/20
MEET OUR TEAM
Over 27 years in the telecommunications, oil and gas, and pharmaceutical industries. Previous general manager of Nikma Pharmaceutical Company, a firm active in importing and producing supplements. Taught strategic management and pharmaceutical marketing at Tehran University of Medical Sciences and Shahid Beheshti University.
A seasoned Chartered Professional Accountant with over 25 years of experience in finance both in public and private sectors. Mr. Tavakoli has helped facilitate many sales and acquisition deals (-100M+) involving retail high-tech, telecommunication as well as wholesale industries. In the past, he has held Director of Finance, Corporate Controller and Senior Accounting positions in Pharmaceuticals, telecommunications, BC Government and Mining industries.
President of The Concosts Group, Mr. Weber is responsible for the management of an umbrella of companies employing in excess of 50 full-time staff members. He is involved with over 47 real estate projects to date (total construction value ~$500 million), including concrete condominium mid/high-rise developments, steel-framed condominium developments,
15+ years experience in genomic research projects and next generation sequencing technologies. PhD at the University of Valencia, Spain, under the Molecular and Evolutionary Genetics and expertise in data science, experimental design, and applications of statistical and Machine Learning methods.
Prof. Dr. Robert Gorter was born and raised in the Netherlands and graduated at the University of Amsterdam in 1971. He specialized in Family and Community Medicine, Internal Medicine, Biostatistics, Addiction Medicine, Tropical Medicine and Oncology (University of Basel, Switzerland). From 1995 on, Dr. Gorter has been advising the German authorities (BfARM), Indian and the Dutch authorities in regard to licensing Cannabis sativa and its cannabinoids for medical use. Over the previous years and on multiple requests from patients around the world, Dr. Gorter has consented to hold on-line consultations for patients needing to know more about Cannabis and if Cannabis would be indicated for their health problems and disease; and prescribe it legally in many countries. Also, for the Dutch, German and Indian medical authorities, Dr. Gorter started a formal Continuous Medical Education (CME) program for doctors on the medical use of Cannabis.
TIMELINE
Contact us
Call us for more information on our project or to explore investment opportunities.
1-604-351-1466
FOR INVESTMENT OPPORTUNITIES
info@XynaRx.com
CORPORATE HEADQUARTERS
Suit 112 – 828 Harbourside Dr. North Vancouver, BC, V7P 3R9
Contact With The Form